Skip to content

Clara Massaneda-Tuneu

2 papers in the library · 7 citations · publishing 2025-2026

Papers

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Psychiatry research February 1, 2025 Adam Bayes, Thanh Vinh Cao, Ana Rita Barreiros et al. 6 citations

Ketamine and its derivatives are increasingly used for treatment-resistant depression, but they can cause side effects during and between treatment sessions. The Ketamine Side Effect Tool (KSET) was designed to monitor these effects, but its length limited its use in clinics. Using retrospective data from three outpatient services, researchers calculated how often side effects occurred within sessions, between sessions, and at follow-up. They then developed a shorter version, the KSET-Revised (KSET-R), which showed good construct and concurrent validity for specific items and an overall tolerability rating. The revised tool is more feasible for clinical practice and is recommended for monitoring side effects in patients receiving ketamine treatment.

Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time.

Translational psychiatry January 23, 2026 Stevan Nikolin, Clara Massaneda-Tuneu, Louise Brettell et al. 1 citation

Electroconvulsive therapy (ECT) leads to a faster reduction in depressive symptoms than ketamine for severe, medication-resistant depression. A meta-analysis of seven studies with 731 participants found that depression scores were slightly lower at baseline in the ketamine group. After adjusting for baseline differences, ECT produced an additional improvement of about 0.02 standardized mean difference per day, amounting to a predicted moderate advantage over ketamine after four weeks. This advantage falls within the range considered clinically meaningful.